Core Viewpoint - Oncolytic viruses (OV) represent a promising therapy in cancer treatment, particularly for glioblastoma, by selectively replicating in tumor cells and activating immune responses [2][3][5]. Group 1: Clinical Trial Findings - A first-in-human phase 1 clinical trial reported safety data for 41 patients with recurrent glioblastoma (rGBM) treated with a modified oncolytic herpes simplex virus (oHSV), which selectively replicates in glioblastoma cells without harming healthy brain tissue [3]. - The treatment led to enhanced anti-cancer immune responses, with patient survival correlating with immune activation characteristics [3][4]. - Single oncolytic virus treatment resulted in deep and persistent T cell infiltration in glioblastoma, activating T cell-mediated cytotoxic responses associated with longer progression-free survival and overall survival [4][5]. Group 2: Immune Response Mechanisms - The study revealed that a single injection of oncolytic virus could transform the immune cold environment of glioblastoma into a hot environment rich in activated cytotoxic T cells, significantly extending patient survival [5]. - Evidence of early T cell activation and tissue residency was observed, with T cells near tumor cells expressing high levels of activation markers, indicating ongoing recognition of tumor antigens [8]. - The expansion of pre-existing tumor-infiltrating T cell clones was noted, correlating with longer overall survival, suggesting that the treatment amplifies existing immune responses [11]. Group 3: Treatment Challenges and Considerations - Despite strong T cell responses, hypoxic tumor regions exhibited T cell exclusion, potentially due to a suppressive microenvironment, which may contribute to treatment resistance [13]. - Long-term use of dexamethasone, a common medication for brain edema, was associated with reduced T cell clonality post-treatment, indicating a need for careful management of corticosteroids to optimize immune responses [14]. - The study emphasizes the importance of combining oncolytic virus therapy with agents that enhance T cell expansion and persistence, as well as anti-VEGF therapies to overcome hypoxic conditions [17].

Core Viewpoint - The article discusses the increasing consumption of fructose and its potential health risks, particularly its role in aggravating inflammation and its association with various diseases, including cancer and metabolic disorders [2][3][4]. Group 1: Fructose Consumption and Health Risks - Fructose is a monosaccharide that has been widely used as a sweetener in beverages and processed foods, leading to a significant increase in its consumption over the past 50 years [2]. - Excessive intake of fructose is linked to various health issues, including high blood sugar, obesity, type 2 diabetes, fatty liver, cardiovascular diseases, and an increased risk of certain cancers such as colorectal, pancreatic, ovarian, and liver cancer [2][3]. - Recent studies indicate that high fructose consumption may also be associated with anxiety disorders, particularly among adolescents [2]. Group 2: Immune System Impact - The impact of fructose on the immune system, particularly its role in regulating acquired immunity and T cell immunity, has not been sufficiently studied [3][6]. - A recent study found that high fructose intake promotes the generation of effector T cells (Th1 and Th17), exacerbating inflammation and potentially worsening inflammatory bowel disease (IBD) [4][7]. - The study suggests that the common antidiabetic drug metformin can reverse the effects of high fructose intake by inhibiting mTORC1 activation and reducing reactive oxygen species (ROS) mediated TGF-β activation, thus alleviating T cell inflammation and colitis [4][9]. Group 3: Mechanisms of Fructose-Induced Inflammation - High fructose intake enhances the differentiation of Th1 and Th17 cells through a glutamine metabolism-dependent pathway that activates mTORC1, contributing to the progression of IBD [7]. - The study highlights that fructose can directly mediate immune responses and disrupt immune homeostasis, leading to increased inflammation [9]. Group 4: Fructose and Cancer Growth - Additional research indicates that fructose may indirectly promote tumor growth by enhancing lipid transfer between organs, providing cancer cells with the necessary lipids for rapid proliferation [13]. - Another study reveals that fructose inhibits the polarization of M1-like tumor-associated macrophages, promoting the development of colorectal cancer through mechanisms that do not rely on its downstream metabolites [15].